

1 Article

# 2 Synthesis and Antiproliferative Activity of 3 Diethylamine Mannich Base of Asymmetrical 4 Mono-Carbonyl Curcumin Analogs against HeLa 5 Cell Lines

6 Pekik Wiji Prasetyaningrum<sup>1</sup>, Anton Bahtiar<sup>1</sup> and Hayun Hayun<sup>1,\*</sup>

7 <sup>1</sup> Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia, 16424;

8 pekikwiji@gmail.com (P.W.P.); anton.bahtiar@gmail.com (A.B.); hayun.ms@ui.ac.id (H.H)

9 \* Correspondence: hayun.ms@ui.ac.id; Tel.: +62-21-727-0031

10 **Abstract:** A series of diethylamine Mannich base of asymmetrical mono-carbonyl analogs of  
11 curcumin (AMACs) were synthesized and evaluated for cytotoxic activity against HeLa Cell lines.  
12 The structures of the synthesized compounds were confirmed on the basis of FTIR, <sup>1</sup>H-NMR,  
13 <sup>13</sup>C-NMR and mass spectral data. Preliminary cytotoxic test using BSLT showed that all the  
14 synthesized compounds exhibited more potent cytotoxic activity than that of curcumin. While  
15 results of MTT assay showed that all the synthesized compounds exhibited more potent  
16 antiproliferative activity against HeLa cell lines than that of cisplatin. Compound **2b** exhibited as  
17 the most potent compound of the series. Compound **2a**, **2b**, **2c**, and **2f** had IC<sub>50</sub> (μM) less than that  
18 of compound **1a**, **1b**, **1c** and **1f** indicating that the addition of diethylamine Mannich base improves  
19 the antiproliferative activity of the parent compound.


20 **Keywords:** diethylamine Mannich base; asymmetrical mono-carbonyl analogs of curcumin;  
21 AMACs; synthesis; cytotoxicity; antiproliferative activity; HeLa cell lines  
22

## 23 1. Introduction

24 The mono-carbonyl analogs of curcumin (MACs) exhibit the potency of 10-30 times for cell lines  
25 and cellular proteins compared to curcumin [1-4]. MACs pharmacokinetic profile will be much more  
26 stable than curcumin, resulting in greater tumor regression [1,5]. The introduction an aminoalkyl  
27 side chain by Mannich reaction in phenolic compounds increases significantly the biological activity  
28 of the compounds [6]. Some of the Mannich bases of symmetrical mono-carbonyl analogs of  
29 curcumin (MACs), heterocyclic chalcone analogs, pterostilbene, and other phenolic compounds  
30 showed significant improvement in cytotoxic activity [7-10].

31 Nowadays, some of the asymmetrical MACs (AMACs) with different constituents on the two  
32 phenyl rings have been developed and reported to show antioxidant, anti-inflammatory,  
33 antimicrobial [11-15] and antitumor properties [16]. However, the study of the Mannich bases of  
34 AMACs as an anti-cancer agent has never been reported. As a continuation of our study in Mannich  
35 bases compound derivatives, herein we report the synthesis and anti-proliferative activity of  
36 AMACs and their diethylamine Mannich base derivatives against HeLa Cells (**Scheme 1**).

37  
38



Scheme 1. The design of the title compounds

39  
40  
41

## 42 2. Materials and Methods

### 43 2.1. Chemistry.

44 2.1.1. *General Procedures.* All solvents, chemicals, and reagents were obtained commercially and used  
45 without purification. Purity tests of the products were performed by the TLC method on silica gel 60  
46 F254 plates (Merck). Melting points were determined in the capillary tube using melting point  
47 apparatus (Stuart Scientific) and are uncorrected. Infrared (IR) spectra were recorded on an FTIR  
48 8400S spectrophotometer (Shimadzu), <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were recorded on NMR  
49 spectrometer (Agilent) at 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C using TMS as internal standard, and  
50 high-resolution mass spectra (HRMS) were measured with a Waters LCT Premier XE (ESI-TOF)  
51 system in negative mode.

52

### 53 2.1.2. *Synthesis of (2E)-2-(phenylmethylidene)cyclohexan-1-one and analogs*

54 The synthesis was performed according to the method of the synthesis of 2-benzylidene acetone  
55 by replacing acetone with cyclohexanone [17]. A mixture of aromatic aldehyde (0.32 mol) and  
56 cyclohexanone (0.88 mol) was added a solution of NaOH (10%) dropwise while stirring for 2 hours.  
57 The mixture was neutralized with dilute HCl to pH 7, separated the organic layer and extracted the  
58 water layer with 16 mL of toluene. The toluene layer was mixed with the organic layer, washed with  
59 16 mL of water, dried with anhydrous sodium sulfate, and evaporated using rotary vacuum  
60 evaporator to give the crude product. The crude product was used as starting material for the next  
61 step without further purification.

62

### 63 2.1.3. *Synthesis of Asymmetrical Mono-carbonyl Analogs of Curcumin (AMACs)(1a-1f)*

64 The synthesis the compounds were performed by the aldol condensation of  
65 (2E)-2-(phenylmethylidene)cyclohexan-1-one or it's analogs and vanillin or p-hydroxybenzaldehyde  
66 under acidic condition, respectively. The mixture of (2E)-2-(phenylmethylidene)cyclohexan-1-one or  
67 it's analogs (0.005 mol) and vanillin or p-hydroxybenzaldehyde (0.01 mol) in ethanol (10 ml) was  
68 heated under reflux condition until dissolved and added a drop of diluted HCl/ethanol (1:1), and  
69 stirred for 30 mins. The progress of the reaction was monitored by thin layer chromatographic  
70 method. Upon completion, the solvent was evaporated, the solid material obtained was triturated  
71 with a cold mixture of glacial acetic acid/water (1:1), and filtered using Buchner funnel. The solid  
72 product obtained was washed with a cold mixture of glacial acetic acid/water (1:1), dried, and  
73 purified by column chromatography with a mixture of the appropriate ratio of n-hexane and ethyl  
74 acetate.

75

76 (2E, 6E)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-6-(phenylmethylidene)cyclohexan-1-one (**1a**). The  
77 compound was a bright yellow powder, in a 50.0 % yield, mp: 149-151 °C and R<sub>f</sub> = 0.8 (ethyl acetate :  
78 n-hexane = 1:2). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3211 (OH), 2999 (CH aromatic), 2837 (CH aliphatic), 1647  
79 (C=O), 1587, 1531, 1448 (C=C), 1174 (C-O). <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>), δ/ppm: 1.80 (m, 2H,  
80 C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.93 (t, 4H, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.91 (s, 3H, OCH<sub>3</sub>); 5.89 (s, 1H, OH); 6.96 (d, 1H,  
81 J=8, H<sub>Ar</sub>); 7.00 (s, 1H, H<sub>Ar</sub>); 7.09 (d, 1H, J=8 Hz, H<sub>Ar</sub>); 7.33 (t, 1H, J=7, H<sub>Ar</sub>); 7.39 (t, 2H, J=7 Hz, H<sub>Ar</sub>); 7.46  
82 (d, 2H, J=7.2 Hz, H<sub>Ar</sub>); 7.75 and 7.79 (s, 1H Ar-CH=C and 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  
83 δ/ppm: 23 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 (2C, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 56 (O-CH<sub>3</sub>), 113, 114, 124, 128, 130,

84 134 (10C, C<sub>Ar</sub>), 136, 137 (4C, -C=C-) 146 (2C, C<sub>Ar</sub>-O), 190 (1C, C=O); HRESIMS (*m/z*) found 319.1346  
 85 ([M-H]<sup>-</sup>), calculated masses of C<sub>21</sub>H<sub>19</sub>O<sub>3</sub>: 319.1334

86  
 87 (2*E*, 6*E*)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-6-[(4-methoxyphenyl)methylidene] cyclohexan-1-one  
 88 (1*b*). The compound was a yellow powder, in a 2.7 % yield, mp: 133-136 °C and R<sub>f</sub> = 0.55 (ethyl  
 89 acetate : n-hexane = 1:2). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3431 (OH), 3003 (CH aromatic), 2935 (CH aliphatic),  
 90 1734 (C=O), 1656, 1593 and 1512 (C=C), 1161 (C-O). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ/ppm: 1.80 (m,  
 91 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.92 (m, 4H, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.84 (s, 3H, CH<sub>3</sub>-O); 3.91 (s, 3H, CH<sub>3</sub>-O);  
 92 5.86 (s, 1H, OH); 6.96 (t, 3H, J=8, H<sub>Ar</sub>); 6.99 (s, 1H, H<sub>Ar</sub>); 7.08 (d, 1H, J=8 Hz, H<sub>Ar</sub>); 7.46 (d, 2H, J=8, Hz,  
 93 H<sub>Ar</sub>); 7.73, 7.76 (s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ/ppm: 23.18  
 94 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 28 (2C, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 55, 56 (2C, OCH<sub>3</sub>), 113, 114, 124, 128, 132 (9C,  
 95 C<sub>Ar</sub>), 134, 137 (4C, -C=C-), 146, 160 (3C, C<sub>Ar</sub>-O) 190 (1C, C=O). HRESIMS (*m/z*) found 349.1432  
 96 ([M-H]<sup>-</sup>), calculated masses of C<sub>22</sub>H<sub>21</sub>O<sub>4</sub>: 349.1440

97  
 98 (2*E*, 6*E*)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-6-[(4-fluorophenyl)methylidene] cyclohexan-1-one  
 99 (1*c*). The compound was a light yellow powder, in a 47.3 % yield, mp: 129-131 °C and R<sub>f</sub> = 0.52 (ethyl  
 100 acetate : n-hexane = 1:2). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3313 (OH), 3003 (CH aromatic), 2939 (CH  
 101 aliphatic), 1734 (C=O), 1656, 1604 and 1514 (C=C), 1220 (C-F), 1155 (C-O). <sup>1</sup>H-NMR (500 MHz,  
 102 CDCl<sub>3</sub>) δ/ppm: 1.82 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.89 (t, 2H, J=7 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.93 (t, 2H,  
 103 J=6 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.93 (s, 3H, CH<sub>3</sub>-O); 5.90 (s, 1H, -OH); 6.96 (d, 1H, J=9 Hz, H<sub>Ar</sub>); 7.00 (s,  
 104 1H, H<sub>Ar</sub>); 7.10 (t, 3H, J=8.2 Hz, H<sub>Ar</sub>); 7.44 (dd, 2H, J=5 Hz, H<sub>Ar</sub>); 7.75 (s, 2H, Ar-CH=C). <sup>13</sup>C NMR (100  
 105 MHz, CDCl<sub>3</sub>) δ/ppm: 23 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 28 (2C, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 56 (1C, OCH<sub>3</sub>), 113, 114,  
 106 115, 116, 125, 129, 132, 134 (9C, C<sub>Ar</sub>), 135, 136, 138, 146 (4C, C=C), 147 (C<sub>Ar</sub>-F), 161, 164 (2C, C<sub>Ar</sub>-O), 190  
 107 (1C, C=O); ); HRESIMS (*m/z*) found 337.1270 ([M-H]<sup>-</sup>), calculated masses of C<sub>21</sub>H<sub>18</sub>FO<sub>3</sub>: 337.1240.

108  
 109 (2*E*, 6*E*)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-6-[(4-chlorophenyl)methylidene] cyclohexan-1-one  
 110 (1*d*). The compound was a light yellow powder, in a 6.1 % yield, mp: 150-154 °C and R<sub>f</sub> = 0.75 (ethyl  
 111 acetate : n-hexane = 1:2). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3296 (OH), 3003 (CH aromatic), 2939 (CH aliphatic),  
 112 1734 (C=O), 1658, 1604 and 1514 (C=C), 1163 (C-O), 833 (C-Cl). <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>),  
 113 δ/ppm: 1.80 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.87 (t, 2H, J=7.3 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.93 (t, 2H, J=7.35  
 114 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.92 (s, 3H, CH<sub>3</sub>-O); 5.86 (s, 1H, OH); 6.96 (d, 1H, J=8 Hz, H<sub>Ar</sub>); 6.99 (s, 1H,  
 115 H<sub>Ar</sub>); 7.08 (d, 1H, J=8 Hz, H<sub>Ar</sub>); 7.37 (d, 2H, J=9 Hz, H<sub>Ar</sub>); 7.39 (d, 2H, J=9 Hz, H<sub>Ar</sub>), 7.72, 7.74 (s, 1H,  
 116 Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ/ppm: 23 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29  
 117 (2C, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 56 (1C, OCH<sub>3</sub>), 113, 114, 125, , 128.51 (C15), 129, 132, 134 (9C, C<sub>Ar</sub>), 134, 135,  
 118 137, 137 (4C, -C=C-), 138 (C<sub>Ar</sub>-Cl), 146 (2C, C<sub>Ar</sub>-O), 190 (1C, C=O). HRESIMS (*m/z*) found 353.0947  
 119 ([M-H]<sup>-</sup>), calculated masses of C<sub>21</sub>H<sub>19</sub>ClO<sub>3</sub>: 353.0945.

120  
 121 (2*E*, 6*E*)-2-[(4-hydroxy-3-methoxyphenyl)methylidene]-6-[(4-methylphenyl)methylidene] cyclohexan-1-one  
 122 (1*e*). The compound was a yellow powder, in a 13.2 % yield, mp: 130-131 °C and R<sub>f</sub> = 0.75 (ethyl  
 123 acetate : n-hexane = 1:2). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3323 (OH), 3007 (CH aromatic), 2939 (CH aliphatic),  
 124 1734 (C=O), 1653, 1593 and 1462 (C=C), 1161 (C-O). <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) δ/ppm: 1.79 (m,  
 125 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.38 (s, 3H, CH<sub>3</sub>-Ar), 2.91 (t, 2H, J=7 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.93 (t, 2H, J=  
 126 7.15 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 3.92 (s, 3H, CH<sub>3</sub>-O); 5.86 (s, 1H, -OH); 6.96 (t, 3H, J=8 Hz, H<sub>Ar</sub>); 6.99 (s,  
 127 1H, H<sub>Ar</sub>); 7.08 (d, 1H, J=8.3 Hz, C15=CH-C18)); 7.22 (d, 2H, J=8 Hz, H<sub>Ar</sub>); 7.37 (d, 2H, J=8 Hz, H<sub>Ar</sub>), 7.74  
 128 and 7.77 (s, 1H, s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ/ppm: 21.54  
 129 (CH<sub>3</sub>-Ar), 23 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 (1C, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 56 (CH<sub>3</sub>-O), 113.40 (C18), 114.56  
 130 (C16), 124,60 (C17), 128.66 (C15), 129.26 (C2, C4), 130.58 (C1,C5), 133.36 (C8), 134.39 (10C, C<sub>Ar</sub>), 136,  
 131 137, 137, 139 (4C, -C=C-), 146 (2C, C<sub>Ar</sub>-O), 190.38 (1C, C=O); HRESIMS (*m/z*) found 333.1492 ([M-H]<sup>-</sup>),  
 132 calculated masses of C<sub>22</sub>H<sub>21</sub>O<sub>3</sub>: 333.1492

133  
 134 (2*E*, 6*E*)-2-[(4-hydroxyphenyl)methylidene]-6-(phenylmethylidene)cyclohexan-1-one (1*f*). The compound  
 135 was a yellow powder, in a 55,5 % yield, mp: 214-216 °C and R<sub>f</sub> = 0.81 (ethyl acetate : n-hexane = 1:2).

136 FTIR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3292 (OH), 3059 (CH aromatic), 2933 (CH aliphatic), 1653 (C=O), 1587  
137 (C=C), 1506 and 1431 (C=C aromatic), 1161 (C-O). <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ /ppm: 1.80 (m,  
138 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.93 (t, 4H, *J*=6 Hz =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 5.1 (s, 1H, OH); 6.88 (d, 2H, *J*=8, H<sub>Ar</sub>);  
139 7.33 (t, 1H, *J*=7 Hz, H<sub>Ar</sub>); 7.42 (m, 4H, H<sub>Ar</sub>), 7.46 (d, 2H, *J*=7 Hz, H<sub>Ar</sub>); 7.75 and 7.79 (s, 1H, s, 1H,  
140 Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ /ppm: 23 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 28  
141 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 115, 128, 129, 130, 133, 134 (11C, C<sub>Ar</sub>), 136, 137 (4C, -C=C-), 156 (1C, C<sub>Ar</sub>-O),  
142 190 (1C, C=O); HRESIMS (*m/z*) found 289.1232 ([M-H]<sup>-</sup>), calculated masses of C<sub>20</sub>H<sub>17</sub>O<sub>2</sub>: 289.1229  
143

#### 144 2.1.4. Synthesis of Diethylamine Mannich Base of AMACs (2a-2f)

145 The synthesis were performed according to the method for the synthesis of di-Mannich bases of  
146 curcumin and the synthesis of 2-[(2,6-dimethylmorpholin-4-yl)methyl]-4-[(E)-2-{3[(E)-2-{3-  
147 [(2,6-dimethylmorpholin-4-yl)methyl]-4-hydroxy-5-methoxyphenyl}ethenyl]-1H-pyrazol-5-yl}ethyl  
148 ]-6-methoxyphenol reported previously [18, 22]. Compound **1a-1f** (2 mmol) was dissolved in  
149 ethanol, cooled in an ice bath, and added diethylamine (5 - 7 mmol) and formaldehyde solution 37%  
150 (5-7 mmol) slowly. The mixture was stirred for 30 min at room temperature and then refluxed for 7-  
151 11 h. The progress of the reaction was monitored by TLC. After the reaction was completed, the  
152 solvent was evaporated to obtain the solid residue. The residue was dissolved in methanol (40 mL)  
153 and evaporated to a residue. The residue was then dissolved in methanol (50 mL), warmed, and  
154 poured slowly with constant stirring into about 400 mL of cold distilled water. The solvent was  
155 decanted and the precipitate obtained was filtered off, washed with cold distilled water, dried at  
156 room temperature and then purified by column chromatography.  
157

158 (2*E*,6*E*)-2-[(3-[(diethylamino)methyl]-4-hydroxy-5-methoxyphenyl)methylidene]-6-(phenylmethylidene)cyclo  
159 hexan-1-one (**2a**). The compound was a caramel-like solid, in a 65.5 % yield, mp: 79-80 °C and R<sub>f</sub> =  
160 0.51 (ethyl acetate: ethanol = 1:1). FTIR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3053 (CH aromatic), 2972 (C-H), 1660  
161 (C=O), 1599 (C=C), 1269 (C-N), 1157 (C-O). <sup>1</sup>H-NMR (500 MHz, CD<sub>3</sub>OD),  $\delta$ /ppm: 1.18 (t, 6H, *J*=7.2  
162 Hz, CH<sub>3</sub>-CH<sub>2</sub>-), 1.77 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.77 (q, 4H, *J*=7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-N), 2.89 and 2.94 (t, 4H,  
163 *J*=7 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 3.85 (s, 3H, CH<sub>3</sub>-O), 3.95 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H, -OH), 6.92 (s, 1H,  
164 H<sub>Ar</sub>), 7.04 (s, 1H, H<sub>Ar</sub>); 7.33 (t, 1H, *J*=8.7 Hz, H<sub>Ar</sub>); 7.40 (t, 2H, *J*=7.4 Hz H<sub>Ar</sub>), 7.45 (d, 2H, *J*=10.9 Hz, H<sub>Ar</sub>),  
165 7.66 and 7.68 (s, 1H, s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$ /ppm: 11  
166 (2C, CH<sub>3</sub>-CH<sub>2</sub>) 24 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 57 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N-), 56  
167 (1C, Ar-CH<sub>2</sub>-N), 57 (1C, CH<sub>3</sub>-O), 115, 122, 126, 126. 129, 130, 131, 134 (10C, C<sub>Ar</sub>), 137, 138, 139 (4C,  
168 -C=C-), 150 and 153 (2C, C<sub>Ar</sub>-O), 192 (1C, C=O); HRESIMS (*m/z*) found 404.2285 ([M-H]<sup>-</sup>), calculated  
169 masses of C<sub>26</sub>H<sub>30</sub>NO<sub>3</sub>: 404.2227  
170

171 (2*E*,6*E*)-2-[(3-[(diethylamino)methyl]-4-hydroxy-5-methoxyphenyl)methylidene]-6-[(4-methoxyphenyl)meth  
172 ylidene]cyclohexan-1-one (**2b**). The compound was an orange sticky powder, in a 46.8 % yield, mp:  
173 98-99 °C and R<sub>f</sub> = 0.51 (ethyl acetate: ethanol = 1:1). FTIR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3059 (CH aromatic), 2970  
174 (CH aliphatic), 1734 (C=O), 1556 (C=C), 1595 and 1510 (C=C aromatic) 1271 (C-N), 1155 (C-O). <sup>1</sup>H  
175 NMR (500 MHz, CD<sub>3</sub>OD),  $\delta$ /ppm: 1.17 (t, 6H, *J*=7, CH<sub>3</sub>-CH<sub>2</sub>-), 1.78 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.77  
176 (q, 4H, *J*=7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-N), 2.88 and 2.92 (t, 2H, *J*=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub> and t, 2H, *J*=5 Hz,  
177 =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 3.81 (s, 3H, CH<sub>3</sub>-O-), 3.85 (s, 3H, CH<sub>3</sub>-O-), 3.91 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H,  
178 -OH), 6.89 (s, 1H, H<sub>Ar</sub>), 6.96 (d, 2H, *J*= 9, H<sub>Ar</sub>), 7.01 (s, 1H, H<sub>Ar</sub>); 7.44 (d, 2H, *J*=9 Hz, H<sub>Ar</sub>), 7.64 and 7.65  
179 (s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD)  $\delta$ /ppm: 11 (2C, CH<sub>3</sub>-CH<sub>2</sub>) 24  
180 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 47 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N-), 56 (1C, CH<sub>3</sub>-O), 56  
181 (1C, CH<sub>3</sub>-O), 57 (1C, Ar-CH<sub>2</sub>-N), 114, 115, 123, 126, 127, 130, 133 (9C, C<sub>Ar</sub>), 134, 136, 138, 139 (4C,  
182 -C=C-), 150, 153 and 162 (3C, C<sub>Ar</sub>-O), 192 (1C, C=O); HRESIMS (*m/z*) found 434.2101 ([M-H]<sup>-</sup>),  
183 calculated masses of C<sub>27</sub>H<sub>32</sub>NO<sub>4</sub>: 434.2332  
184

185 (2*E*,6*E*)-2-[(3-[(diethylamino)methyl]-4-hydroxy-5-methoxyphenyl)methylidene]-6-[(4-fluorophenyl)methyl  
186 idene]cyclohexan-1-one (**2c**). The compound was an orange powder, in a 33,01 % yield, mp: 79-81 °C  
187 and R<sub>f</sub> = 0.48 (ethyl acetate: ethanol = 1:1). FTIR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3041 (CH aromatic), 2937 (CH

188 aliphatic), 1734 (C=O), 1656 (C=C), 1595 and 1492 (C=C aromatic) 1271 (C-N), 1224 (C-F), 1157 (C-O).  
189 <sup>1</sup>H-NMR (500 MHz, CD<sub>3</sub>OD), δ/ppm: 1.18 (t, 6H, J=7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-), 1.77 (m, 2H,  
190 C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.77 (q, 4H, J=7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-N), 2.87 and 2.94 (t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>  
191 and t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.85 (s, 3H, CH<sub>3</sub>-O), 3.93 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H, -OH),  
192 6.92 (s, 1H, H<sub>Ar</sub>), 7.03 (s, 1H, H<sub>Ar</sub>); 7.14 (d-d, 2H, J=9 Hz, H<sub>Ar</sub>), 7.49 (d-d, 2H, J=6 Hz, H<sub>Ar</sub>), 7.65 and  
193 7.66 (s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD) δ/ppm: 11 (2C, CH<sub>3</sub>-CH<sub>2</sub>)  
194 24 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 47 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N-), 55 (1C, CH<sub>3</sub>-O),  
195 57 (1C, Ar-CH<sub>2</sub>-N), 114, 116, 117, 122, 126, 133, 134 (9C, C<sub>Ar</sub>), 136, 138, 140, 153 (4C, -C=C-), 169 and  
196 163 (2C, C<sub>Ar</sub>-O), 165 (1C, C<sub>Ar</sub>-F), 192 (1C, C=O); HRESIMS (m/z) found 422.2178 ([M-H]<sup>-</sup>), calculated  
197 masses of C<sub>26</sub>H<sub>29</sub>FNO<sub>3</sub>: 422.2132.

198  
199 (2E,6E)-2-({3-[(diethylamino)methyl]-4-hydroxy-5-methoxyphenyl}methylidene)-6-[(4-chlorophenyl)methylidene]cyclohexan-1-one (2d). The compound was an orange powder, in a 76.93 % yield, mp: 95-97 °C  
200 and R<sub>f</sub> = 0.45 (ethyl acetate: ethanol = 1:1). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3032 (CH aromatic), 2972 (CH  
201 aliphatic), 1734 (C=O), 1656 (C=C), 1597 and 1491 (C=C aromatic) 1271 (C-N), 1157 (C-O), 839 (C-Cl).  
202 <sup>1</sup>H-NMR (500 MHz, CD<sub>3</sub>OD), δ/ppm: 1.18 (t, 6H, J= 7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-), 1.78 (m, 2H,  
203 C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 2.79 (q, 4H, J= 7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-N), 2.87 and 2.95 (t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>  
204 and t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.85 (s, 3H, CH<sub>3</sub>-O), 3.94 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H, -OH),  
205 6.93 (s, 1H, H<sub>Ar</sub>), 7.04 (s, 1H, H<sub>Ar</sub>); 7.42 (d, 2H, J=9 Hz, H<sub>Ar</sub>), 7.44 (d, 2H, J=9 Hz, H<sub>Ar</sub>), 7.63 and 7.66 (s,  
206 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD) δ/ppm: 11 (2C, CH<sub>3</sub>-CH<sub>2</sub>), 24 (1C,  
207 C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 48 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N), 55 (1C, CH<sub>3</sub>-O), 57 (1C,  
208 Ar-CH<sub>2</sub>-N), 115, 122, 126, 130, 133, 134 (9C, C<sub>Ar</sub>), 135, 136, 139 (4C, -C=C-), 153 and 150 (2C, C<sub>Ar</sub>-O),  
209 153.33 (1C, C<sub>Ar</sub>-Cl), 191.54 (1C, C=O); HRESIMS (m/z) found 438.1881 ([M-H]<sup>-</sup>), calculated masses of  
210 C<sub>26</sub>H<sub>29</sub>ClNO<sub>3</sub>: 438.1837

211  
212  
213 (2E,6E)-2-({3-[(diethylamino)methyl]-4-hydroxy-5-methoxyphenyl}methylidene)-6-[(4-methylphenyl)methylidene]cyclohexan-1-one (2e). The compound was an orange sticky powder, in a 76.9 % yield, mp: 86-89  
214 °C and R<sub>f</sub> = 0.48 (ethyl acetate: ethanol = 1:1). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3032 (CH aromatic), 2974 (CH  
215 aliphatic), 1734 (C=O), 1664 (C=C), 1599 and 1498 (C=C aromatic) 1269 (C-N), 1157 (C-O). <sup>1</sup>H-NMR  
216 (500 MHz, CD<sub>3</sub>OD), δ/ppm: 1.18 (t, 6H, J= 7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-), 1.77 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 2.35 (s,  
217 3H, CH<sub>3</sub>-Ar), 2.80 (q, 4H, J= 7 Hz, CH<sub>3</sub>-CH<sub>2</sub>-N), 2.90 and 2.94 (t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub> and t,  
218 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>); 3.85 (s, 3H, CH<sub>3</sub>-O), 3.94 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H, -OH), 6.92 (s,  
219 1H, H<sub>Ar</sub>), 7.04 (s, 1H, H<sub>Ar</sub>); 7.23 (d, 2H, J=7.85 Hz, H<sub>Ar</sub>), 7.37 (d, 2H, J=7.9 Hz, H<sub>Ar</sub>), 7.65 and 7.67 (s, 1H,  
220 Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C-NMR (100 MHz, CD<sub>3</sub>OD) δ/ppm: 11 (2C, CH<sub>3</sub>-CH<sub>2</sub>), 21 (CH<sub>3</sub>-Ar),  
221 24 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (2C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 48 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N), 56 (1C, CH<sub>3</sub>-O), 57  
222 (1C, Ar-CH<sub>2</sub>-N), 115, 122, 126, 127, 130, 132, 134 (10C, C<sub>Ar</sub>), 137, 138, 139, 140 (4C, -C=C-), 150 and  
223 153 (2C, C<sub>Ar</sub>-O), 192 (1C, C=O); HRESIMS (m/z) found 419.1925 ([M-H]<sup>-</sup>), calculated masses of  
224 C<sub>27</sub>H<sub>32</sub>NO<sub>4</sub>: 419.2461.

225  
226  
227 (2E,6E)-2-({3-[(diethylamino)methyl]-4-hydroxyphenyl}methylidene)-6-(phenylmethylidene)cyclohexan-1-one  
228 (2f). The compound was a yellow sticky powder, in a 56,0 % yield, mp: 62-65 °C and R<sub>f</sub> = 0.5 (ethyl  
229 acetate: ethanol = 1:1). FTIR (KBr) ν<sub>max</sub> cm<sup>-1</sup>: 3049 (CH aromatic), 2970 (CH aliphatic), 1734 (C=O),  
230 1662 (C=C), 1610 and 1494 (C=C aromatic), 1298 (C-N), 1155 (C-O). <sup>1</sup>H-NMR (500 MHz, CD<sub>3</sub>OD),  
231 δ/ppm: 1.16 (t, 6H, J= 7,15 Hz, CH<sub>3</sub>-CH<sub>2</sub>-), 1.79 (m, 2H, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 2.75 (q, 4H, J= 7.2 Hz,  
232 CH<sub>3</sub>-CH<sub>2</sub>-N), 2.94 (m, 4H, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 3.89 (s, 2H, Ar-CH<sub>2</sub>-N), 4.86 (s, 1H, -OH), 6.77 (s, 1H,  
233 H<sub>Ar</sub>), 7.26 (s, 1H, H<sub>Ar</sub>); 7.35 (t, 1H, J=7.15 Hz, H<sub>Ar</sub>), 7.39 (t, 1H, J=7.7 Hz, H<sub>Ar</sub>), 7.43 (d, 2H, J=7.35 Hz,  
234 H<sub>Ar</sub>), 7.47 (d, 2H, J= 9 Hz, H<sub>Ar</sub>), 7.70 and 7.71 (s, 1H, Ar-CH=C and s, 1H, C=CH-Ar). <sup>13</sup>C NMR (100  
235 MHz, CD<sub>3</sub>OD) δ/ppm: 11 (2C, CH<sub>3</sub>-CH<sub>2</sub>), 24 (1C, C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 29 and 30 (t, 2H, J=5 Hz,  
236 =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub> and t, 2H, J=5 Hz, =C-CH<sub>2</sub>-C<sub>cyclohexanone</sub>), 48 (2C, CH<sub>3</sub>-CH<sub>2</sub>-N), 57 (1C, Ar-CH<sub>2</sub>-N),  
237 118, 123, 127, 129, 130, 131, 133, 133, 134 (11C, C<sub>Ar</sub>), 137, 138, 140, 139 (4C, -C=C-), 162 (1C, C<sub>Ar</sub>-O),  
238 192 (1C, C=O); HRESIMS (m/z) found 374.2303 ([M-H]<sup>-</sup>), calculated masses of C<sub>27</sub>H<sub>32</sub>NO<sub>4</sub>: 374.2121.

239

### 240 3.2. Cytotoxicity Test

241

#### 242 3.2.1. Brine Shrimp Lethality Test

243 The assay was carried out according to the principle and protocol previously described by  
244 Meyer [19-20], with slight modification. *Artemia salina* L. eggs were inserted in a box that containing  
245 seawater, the box was placed under UV lamp, after 48 hours the eggs hatched into larvae and ready  
246 for the test. The compound (1a-1f, 2a-2f) were diluted in 10 mL seawater that contains 10 larvae (1%  
247 DMSO (v/v)) until concentration 20, 200, 500, and 1000 ppm. After 24 hours, the live and dead  
248 shrimp were counted. The mortality rate (%) was obtained by comparing the number of total dead  
249 larvae and the total number of larvae. The LC<sub>50</sub> values for a given compound was obtained by  
250 calculating according to the linear regression formula:  $y = a + b x$ ;  $y = \% \text{ mortality}$ ,  $x = \log C$ .

251

#### 252 3.2.2. MTT Proliferation Assay

253 The method refers to MTT proliferation assay protocol by American Type Culture Collection  
254 [21]. HeLa cells line were seeded into 96-well plates at a density of 1000-10000 cells per well,  
255 replenished with 5% heat-inactivated serum, 100 U/mL penicillin, and 100 µg/mL streptomycin.  
256 Cells were incubated at 37°C in 5% CO<sub>2</sub> for 24 h. Various concentrations of tested compounds (100  
257 µL) were added to each well of the plate and incubated for 48 h. After that, a fresh solution of methyl  
258 thiazolyl tetrazolium (MTT) reagent (10 µL) was added to each well and then the plate was  
259 incubated in a CO<sub>2</sub> incubator for 3 h. After a purple precipitate was obtained, the cells were  
260 dissolved in DMSO (100 µL) and were recorded their optical density at 515 nm. Percent growth  
261 inhibition was calculated by the following formula :

262

263

$$\% \text{ Proliferation cells inhibition} = 100 - \{(At - Ab) / (Ac - Ab)\} \times 100\%$$

264

At = absorption of test compound, Ab = absorption of blank, Ac = absorption of control.


265

266 IC<sub>50</sub> values were calculated for a given compound was obtained by calculating according to the  
267 linear regression formula:  $y = a + b x$ ;  $y = \% \text{ proliferation cells inhibition}$ ,  $x = \log C$ .

## 268 3. Results and Discussion

### 269 3.1. Chemistry

270 The title compounds were synthesized stepwise by the method summarized in **Schemes 2**. The  
271 intermediate compounds, (2E)-2-(phenylmethylidene)cyclohexan-1-one and analogs, was  
272 synthesized by the Claisen-Schmidt reaction between benzaldehyde or its analogs with  
273 cyclohexanone in the presence of aqueous alkali according to the preparation method of  
274 4-phenylbut-3-en-2-one [17]. The aldol condensation of the intermediate compounds obtained with  
275 vanilin or p-hydroxybenzaldehyde in addition of diluted HCl/ethanol (1:1) under reflux conditions  
276 for 30 min gave asymmetrical mono-carbonyl of curcumin (AMACs) (**1a-1f**). Finally, the Mannich  
277 reaction of **1a-1f** with diethylamine and formaldehyde at reflux condition in ethanol for 7-11 h (TLC  
278 monitoring) afforded the title compounds **2a-2f** [18].



279

280

Scheme 2. Synthesis of the title compounds (2a-2f)

281 The IR spectra of compounds **1a-1f** showed absorption bands at 3,200–3,500 cm<sup>-1</sup> due to  
 282 the presence of the OH group. The bands at about 1,100 cm<sup>-1</sup> correspond C-O-C ether, while the  
 283  $\alpha,\beta$ -unsaturated carbonyl groups of the AMACs are observed as strong bands at about 1,600  
 284 cm<sup>-1</sup>. In the <sup>1</sup>H-NMR spectra, the protons of the OH group appear as a broad singlet at  $\delta$  5.10 or  
 285 5.85-8.90 ppm, while the two protons of the ethenyl chain of the compounds appeared as two  
 286 singlet at 7.72-7.79 ppm (2H, respectively) indicate the asymmetrical compound. The IR spectra  
 287 of compounds **2a-2f** showed the disappearance of OH phenolic. The bands at 1,151–1,271 cm<sup>-1</sup>  
 288 correspond to C-O-C and C-N, while the  $\alpha,\beta$ -unsaturated carbonyl groups of the compounds  
 289 are observed as strong bands at 1,734 cm<sup>-1</sup>. In the <sup>1</sup>H-NMR spectra, the protons of the OH  
 290 group appear as a broad singlet at  $\delta$  4.86 ppm, and the two protons of the ethenyl chain of the  
 291 compounds are observed as two singlets at a range of 7.63-7.71 ppm (1H, respectively). The  
 292 protons of the diethylamine groups are observed at 1.16-1.18 as doublet and 2.75-2.80 ppm as a  
 293 quintet, while the protons of methylene adjacent N to phenyl ring are observed as a singlet at  
 294 3.90-3.95 ppm. The structures were further supported by <sup>13</sup>C-NMR and HR-ESI-MS of the  
 295 compounds which showed the complete agreement with the assigned molecular structures.

296

### 3.2. Cytotoxicity Activity

297

#### 3.2.1. Brine shrimp lethality test (BSLT)


298 The brine shrimp lethality test (BSLT) was used as a preliminary bioassay to predict the toxicity  
 299 level of the synthesized compounds. It is a rapid, inexpensive, and simple method, and need not  
 300 special equipment or training. The results of BSLT bioassay of the synthesized compounds are  
 301 shown in Table 1. All the synthesized compounds (**1a-1f** and **2a-2f**) exhibited LC<sub>50</sub> < 1000  $\mu$ g/mL,  
 302 indicating to have cytotoxic activity. Compound **1e**, the AMAC which has methyl group and  
 303 compound **2d**, the diethylamine Mannich base of AMAC which has Cl group in the phenyl ring  
 304 exhibited LC<sub>50</sub>  $\leq$  30  $\mu$ g/mL, indicating to have very active as cytotoxic compound [19-20]. Except for  
 305 compounds **2a** and **2e**, all the synthesized compounds is more active than that of curcumin having  
 306 the value of LC<sub>50</sub> = 210.30  $\mu$ g/mL, and only compounds **1b**, **1f**, **2a** and **2e** having cytotoxic activity  
 307 lower than the common drug used for cervical cancer treatment, cisplatin, having the value of LC<sub>50</sub>  
 308 = 106.71  $\mu$ g/mL [19]. Except compound **2a** and **2d**, the diethylamine Mannich base of AMACs are  
 309 generally more active as the cytotoxic agent than that of the parent AMACs.

310

311

## 312 2.2.2. Anti-proliferative activity

313 The MTT cell viability assay was used to measure the anti-proliferative activity of the  
 314 synthesized compounds against HeLa Cell lines using cisplatin as a positive control. The method has  
 315 been widely accepted as a reliable cell proliferation test. In the method, yellow tetrazolium was  
 316 reduced by metabolically active cells, partially by dehydrogenase enzymes, to promote equivalent  
 317 reductions such as NADH and NADPH. The intracellular purple formazan obtained was dissolved  
 318 and quantified by means of spectrophotometry. When metabolic events cause apoptosis or necrosis,  
 319 the cell viability will be reduced [21]. Almost all the synthesized compounds (**1a-1f** and **2a-2d**, and  
 320 **2f**) exhibited more potent antiproliferative activity against HeLa cell lines than that of cisplatin  
 321 (Table 1, Figure 1). Compound **2b**, which has an OCH<sub>3</sub> group in the R1 position and diethylamine  
 322 Mannich base in the R4 position exhibited as the most potent compound of the series. The IC<sub>50</sub> (μM)  
 323 of compound **2a**, **2b**, **2c** and **2f** had less than that of compound **1a**, **1b**, **1c** and **1f** indicating that  
 324 addition of diethylamine Mannich base improves the antiproliferative activity of the parent  
 325 compound. The improvement of the activity may be due to the additional number of molecular sites  
 326 for electrophilic attack by cellular constituents compared to the parent compounds [6-7].



327


328

Figure 1. Antiproliferative activity of the synthesized compounds (**1a-1f** and **2a-2f**)

329

330

Table 1. Cytotoxicity activity of the title compound



331

No	Compound	Substituents				BSLT LC <sub>50</sub> (μg/mL)	MTT <sup>1)</sup> IC <sub>50</sub> (μM) <sup>2)</sup>
		R1	R2	R3	R4		
1	<b>1a</b>	H	OCH <sub>3</sub>	OH	H	62.95	38.30 ± 0.91
2	<b>1b</b>	OCH <sub>3</sub>	OCH <sub>3</sub>	OH	H	112.97	40.90 ± 0.43
3	<b>1c</b>	F	OCH <sub>3</sub>	OH	H	59.97	32.83 ± 0.52
4	<b>1d</b>	Cl	OCH <sub>3</sub>	OH	H	72.27	25.43 ± 0.37
5	<b>1e</b>	CH <sub>3</sub>	OCH <sub>3</sub>	OH	H	26.30	35.44 ± 1.29
6	<b>1f</b>	H	H	OH	H	146.21	43.69 ± 1.21
7	<b>2a</b>	H	OCH <sub>3</sub>	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	373.25	34.72 ± 0.22

8	<b>2b</b>	OCH <sub>3</sub>	OCH <sub>3</sub>	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	34.91	23.64 ± 0.14
9	<b>2c</b>	F	OCH <sub>3</sub>	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	37.41	27.14 ± 0.26
10	<b>2d</b>	Cl	OCH <sub>3</sub>	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	13.06	26.86 ± 0.30
11	<b>2e</b>	CH <sub>3</sub>	OCH <sub>3</sub>	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	714.49	49.85 ± 0.19
12	<b>2f</b>	H	H	OH	CH <sub>2</sub> N(CH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub>	95.49	29.30 ± 0.35
13	Curcumin					210.30 <sup>[19]</sup>	n.t <sup>3)</sup>
14	Cisplatin					106.71 <sup>[19]</sup>	47.48 ± 1.37

332 <sup>1)</sup>Againts HeLa cell lines; <sup>2)</sup>values are the mean ± SD (n = 3); <sup>3)</sup>n.t = not tested

333

### 334 5. Conclusions

335 A series of diethylamine Mannich base of asymmetrical mono-carbonyl analogs of curcumin  
 336 (AMACs) were successfully synthesized. Almost all the synthesized compounds exhibited more  
 337 potent antiproliferation against HeLa cell lines than that of cisplatin. Generally, the IC<sub>50</sub> of the  
 338 diethylamine Mannich base of AMACs compounds were less than that of the parent compound,  
 339 indicated that addition of diethylamine Mannich base improves the antiproliferative activity of the  
 340 parent compound. This result indicates that the AMACs compounds and their diethylamine  
 341 Mannich base derivatives might serve as a potential agent for the treatment of cervical cancer.

342 **Acknowledgments:** We thank the Directorate of Research and Community Services, University of Indonesia,  
 343 Depok, Indonesia, and the Directorate of Research and Community Services, Directorate of Higher Education of  
 344 the Ministry of Research, Technology and Higher Education of the Republic of Indonesia, for the financial  
 345 support of this research. We are also thankful to Chemistry Study Program, Faculty of Natural Sciences,  
 346 Bandung Institute of Technology (ITB), Bandung, Indonesia, for recording NMR spectral data, to Central  
 347 Laboratory of Universitas Padjadjaran, Bandung, Indonesia for recording HR-MS data, to the Department of  
 348 Chemistry Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia for MTT viability assay and to Center  
 349 for Chemistry Research of the Indonesian Institute of Sciences, Serpong, Tangerang, Indonesia for BSLT.

350 **Author Contributions:** H.H. and A.B. conceived, and designed the experiments; P.W. performed the  
 351 experiments; H.H. and P.W. analyzed the data; H.H. and P.W. wrote the paper.

352 **Conflicts of Interest:** The authors declare no conflict of interest.

### 353 References

354

- 355 1. Shetty, D., Kim, Y.J., Shim, H. and Snyder, J.P., (2015). Eliminating the Heart from the Curcumin  
 356 Molecule: Monocarbonyl Curcumin Mimics (MACs). *Molecules*, 20, 249-292.
- 357 2. Ohori, H., Yamakoshi, H., Tomizawa, M. et al. (2006). Synthesis and biological analysis of new  
 358 curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer, *Mol Cancer*  
 359 *Ther.* 5: 2563-2571
- 360 3. Yin, S., Zheng, X., Yao, X., Wang, Y., Liao, D. (2013). Synthesis and Anticancer Activity of  
 361 Mono-Carbonyl Analogues of Curcumin, *J Cancer Ther*, 4, 113-123
- 362 4. Adams, B.K. et al. (2004). Synthesis and biological evaluation of novel curcumin  
 363 analogs as anti-cancer and anti-angiogenesis agents, *Bioorg. Med. Chem.*, 12 (14),  
 364 3871-3883.
- 365 5. Liang, G., Shao, L., Wang, Y., Zhao, C., Chu, Y., Xiao, J., Zhao, Y., Li, X. and Yang, S. 2009.  
 366 Exploration and synthesis of curcumin analogues with improved structural stability  
 367 both in vitro and in vivo as cytotoxic agents. *Bioorg. Med. Chem.*, 17, 2623-2631.
- 368 6. Bala, S., Sharma, N., Kajal, A., Kamboj, S., & Saini, V. (2014). Mannich Bases: An Important  
 369 Pharmacophore in Present Scenario. *Intl J of Med Chem*, Vol. 2014: 1-15.
- 370 7. Liu, C., Dong, L., Wang, S., Wang, Q. (2015). Synthesis and antiproliferative activity of pterostilbene  
 371 and 3'-methoxy pterostilbene Mannich base derivatives against Hela cells. *Mol Divers*, 19:737-743

- 372 8. Yerdelen, K.O., Gul, H.I., Sakagami, H. and Umemura, N. (2014). Synthesis and biological evaluation of  
373 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one and its aminomethyl derivatives. *J*  
374 *Enzyme Inhib Med Chem*, Early Online: 1–6.
- 375 9. Reddy, M.V.B., Su, C-R., Chiou, W-F., Liu, Y-N., Chen, R.Y., Bastow, K.F., Lee, K-H., Wu, T-S. (2008).  
376 Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as  
377 cytotoxic agents, *Bioorg & Med Chem*. 16, 7358–7370
- 378 10. Roman, G. (2015). Mannich bases in medicinal chemistry and drug design. *Eur. J. Med. Chem.* 89,  
379 743-816. <http://dx.doi.org/10.1016/j.ejmech.2014.10.076>
- 380 11. Zhao, C., Liu, Z. and Liang, G. (2013). Promising curcumin-based drug design: Monocarbonyl  
381 analogues of curcumin (MACs). *Curr. Pharm. Res.*, 19, 2114–2135
- 382 12. Zhang, Y., Zhao, L., Wu, J., Jiang, X., Dong, L., Xu, F., Liang, G. (2014). Synthesis and evaluation of a  
383 series of novel asymmetrical curcumin analogs for the treatment of inflammation. *Molecules*, 19(6),  
384 7287–7307. <https://doi.org/10.3390/molecules19067287>
- 385 13. Zhang, Y. et al., (2014.b). Discovery and evaluation of novel anti-inflammatory derivatives of natural  
386 bioactive curcumin. *Drug Design, Development and Therapy*, 8, 2161–2171
- 387 14. Aluwi, M.F.M.F., Rullah, K., Yamin, B.M., Leong, S.W., Bahari, M. N.A, Lim, S. J., Lam, K. W. (2016).  
388 Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on  
389 prostaglandin E2 production in LPS-induced murine and human macrophages cell lines. *Bioorg.*  
390 *Med. Chem. Let.* 26(10), 2531–2538. <https://doi.org/10.1016/j.bmcl.2016.03.092>
- 391 15. Bandgar, B. P., Kinkar, S. N., Chavan, H. V., Jalde, S. S., Shaikh, R. U., & Gacche, R. N. (2014).  
392 Synthesis and biological evaluation of asymmetric indole curcumin analogs as potential  
393 anti-inflammatory and antioxidant agents. *J. Enzyme Inhib Med. Chem.* 29(1), 7–11.  
394 <https://doi.org/10.3109/14756366.2012.743536>
- 395 16. Li, Q., Chen, J., Luo, S., Xu, J., Huang, Q., Liu, T. (2015). Synthesis and assessment of the  
396 antioxidant and antitumor properties of asymmetric curcumin analogues. *Eur J Med Chem*, 93  
397 461-469
- 398 17. Furniss, B.S., Hannaford, A.J., Rogers, V., et al. (1989). *Vogel's textbook of practical organic chemistry*, 5th  
399 edition. Longman Group Ltd. London, 1032-1033.
- 400 18. Geschickter, C. F., & Meadow, J. R. (1969). *United States Patent* No. 3,479,345.
- 401 19. Meyer, B. N., Ferrigni, N. R., Putnam, J.E., Jacobson, L. B., Nichols, D. E., and McLaughlin, J. L., (1982),  
402 Brine shrimp: a convenient general bioassay for active plant constituents. *Planta Medica*, 45:31-34.
- 403 20. Lisdawati, W. B. (2006). Brine Shrimp Lethality Test (Bslt) Dari Berbagai Fraksi Ekstrak Daging  
404 Buah Dan Kulit Biji Mahkota Dewa. *Bul. Penel. Kes.*, 34, No. 3, 2006:111 - 118.
- 405 21. Plumb, J.A. (2004). Cell sensitivity assays: The MTT assay. *Methods Mol Med*. 88:165-9.
- 406 22. Untung, J., Iskandarsyah, I., & Hayun, H. (2017). 2-[(2,6-Dimethylmorpholin-4-yl)methyl]-4-  
407 [(E)-2-[3-[(E)-2-[3-[(2,6-dimethylmorpholin-4-yl)methyl]-4-hydroxy-5-methoxyphenyl]ethenyl]-1H-p  
408 yrazol-5-yl]ethenyl]-6-methoxyphenol. *Molbank*, 2017(3), M949. <https://doi.org/10.3390/M949>
- 409